Skip to main content

Table 1 Baseline characteristics of study subjects at their initial ischemic stroke or TIA events, 2007–2016

From: Impact of multiple cardiovascular medications on mortality after an incidence of ischemic stroke or transient ischemic attack

Cardiovascular treatment groups

 

Total, n = 52,619

0 medication, n = 4259 (8.1%)

1 medication, n = 4837 (9.2%)

2 medications, n = 10,705 (20.3%)

3 medications, n = 12,112 (23.0%)

4 medications, n = 10,197 (19.4%)

5 medications, n = 6177 (11.7%)

≥ 6 medications, n = 4332 (8.2%)

P value

Sex, % women

27,419 (52.1)

2256 (53.0)

2654 (54.9)

5507 (51.4)

6096 (50.3)

5283 (51.8)

3294 (53.3)

2329 (53.8)

< 0.01

Age, (years), mean ± SD

72.0 ± 11.9

71.7 ± 13.3

71.9 ± 13.6

70.7 ± 12.5

71.8 ± 11.7

72.6 ± 11.1

72.9 ± 10.7

73.1 ± 10.6

< 0.01

Smoking (%)

 Current

9847 (18.7)

877 (20.6)

911 (18.8)

2252 (21.0)

2401 (19.8)

1822 (17.9)

948 (15.4)

636 (14.7)

 

 Former

16,458 (31.3)

1186 (27.9)

1349 (27.9)

3144 (29.4)

3855 (31.8)

3304 (32.4)

2121 (34.3)

1499 (34.6)

 

 Never

24,507 (46.6)

1997 (46.9)

2364 (48.9)

4930 (46.1)

5442 (44.9)

4767 (46.8)

2929 (47.4)

2078 (48.0)

 

 Missing

1807 (3.4)

199 (4.7)

213 (4.4)

379 (3.5)

414 (3.4)

304 (3.0)

179 (2.9)

119 (2.8)

 

Alcohol (%)

 Current

26,023 (49.5)

1923 (45.2)

2132 (44.1)

5152 (48.1)

6133 (50.6)

5216 (51.2)

3222 (52.2)

2245 (51.8)

 

 Former

1728 (3.3)

116 (2.7)

189 (3.9)

355 (3.3)

410 (3.4)

318 (3.1)

213 (3.5)

127 (2.9)

 

 Never

8658 (16.5)

712 (16.7)

788 (16.3)

1700 (15.9)

1920 (15.9)

1659 (16.3)

1070 (17.3)

809 (18.7)

 

 Missing

16,210 (30.8)

1508 (35.4)

1728 (35.7)

3498 (32.7)

3649 (30.1)

3004 (29.5)

1672 (27.1)

1151 (26.6)

 

BMI status (%)

 Normal (18.5–24.9 kg/m2)

12,506 (23.8)

1052 (24.7)

1327 (27.4)

2786 (26.0)

2922 (24.1)

2350 (23.1)

1299 (21.0)

770 (17.8)

 

 Overweight (25.0–29.9 kg/m2)

14,897 (28.3)

1080 (25.4)

1229 (25.4)

2879 (26.9)

3408 (28.1)

3062 (30.0)

1933 (31.3)

1306 (30.2)

 

 Obese (≥ 30.0 kg/m2)

11,131 (21.2)

715 (16.8)

670 (13.9)

1748 (16.3)

2410 (19.9)

2382 (23.4)

1727 (28.0)

1479 (34.1)

 

 Underweight (< 18.5 kg/m2)

1075 (2.0)

109 (2.6)

182 (3.8)

268 (2.5)

272 (2.3)

151 (1.5)

58 (0.9)

35 (0.8)

 

 Missing

13,010 (24.7)

1303 (30.6)

1429 (29.5)

3024 (28.3)

3100 (25.6)

2252 (22.1)

1160 (18.8)

742 (17.1)

 

BP status (%)

 Normal (BP < 140/90 mmHg)

21,263 (40.4)

1608 (37.8)

2191 (45.3)

4537 (42.4)

4780 (39.5)

3966 (38.9)

2432 (39.4)

1749 (40.4)

 

 Stage 1 hypertension (BP ≥ 140/90 mmHg)

15,626 (29.7)

1066 (25.0)

1221 (25.2)

2841 (26.5)

3658 (30.2)

3293 (32.3)

2109 (34.1)

1438 (33.2)

 

 Stage 2 hypertension (BP ≥ 160/100 mmHg)

5166 (9.8)

355 (8.3)

332 (6.9)

766 (7.2)

1198 (9.9)

1184 (11.6)

765 (12.4)

566 (13.1)

 

 Stage 3 hypertension (systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg)

2413 (4.6)

154 (3.6)

129 (2.7)

284 (2.7)

508 (4.2)

578 (5.7)

406 (6.6)

354 (8.2)

 

 Missing

8078 (15.4)

1070 (25.1)

958 (19.8)

2263 (21.1)

1953 (16.1)

1159 (11.4)

454 (7.4)

221 (5.1)

 

TC status (%)

 Optimal (< 5.2 mmol/L)

16,562 (31.5)

995 (23.4)

1092 (22.6)

2648 (24.7)

3560 (29.4)

3636 (35.7)

2571 (41.6)

2060 (47.6)

 

 Intermediate (5.3–6.2 mmol/L)

7898 (15.0)

519 (12.2)

626 (12.9)

1596 (14.9)

1929 (15.9)

1598 (15.7)

974 (15.8)

656 (15.1)

 

 High (> 6.2 mmol/L)

4510 (8.6)

314 (7.4)

386 (8.0)

921 (8.6)

1111 (9.2)

902 (8.9)

551 (8.9)

325 (7.5)

 

 Missing

23,649 (44.9)

2431 (57.1)

2733 (56.5)

5540 (51.8)

5512 (45.5)

4061 (39.8)

2081 (33.7)

1291 (29.8)

 

Townsend score (%)

 1 (least deprived)

10,959 (20.8)

809 (19.0)

1037 (21.4)

2256 (21.1)

2627 (21.7)

2155 (21.1)

1248 (20.2)

827 (19.1)

 

 2

10,833 (20.6)

851 (20.0)

1058 (21.9)

2216 (20.7)

2496 (20.6)

2083 (20.4)

1306 (21.1)

823 (19.0)

 

 3

9949 (18.9)

827 (19.4)

952 (19.7)

2051 (19.2)

2168 (17.9)

1932 (19.0)

1173 (19.0)

846 (19.5)

 

 4

8613 (16.4)

745 (17.5)

734 (15.2)

1716 (16.0)

2011 (16.6)

1639 (16.1)

1004 (16.3)

764 (17.6)

 

 5 (most deprived)

5995 (11.4)

494 (11.6)

515 (10.7)

1255 (11.7)

1400 (11.6)

1113 (10.9)

724 (11.7)

494 (11.4)

 

 Missing

6270 (11.9)

533 (12.5)

541 (11.2)

1211 (11.3)

1410 (11.6)

1275 (12.5)

722 (11.7)

578 (13.3)

 

History of PCI (%)

262 (0.5)

13 (0.3)

6 (0.1)

26 (0.2)

42 (0.4)

51 (0.5)

43 (0.7)

81 (1.9)

 

Comorbidity (%)

 Hypertension

29,382 (55.8)

1802 (42.3)

1604 (33.2)

3547 (33.1)

6353 (52.5)

7208 (70.7)

5058 (81.9)

3810 (88.0)

< 0.01

 Hyperlipidaemia

7510 (14.3)

433 (10.2)

463 (9.6)

1257 (11.7)

1644 (13.6)

1629 (16.0)

1187 (19.2)

897 (20.7)

< 0.01

 Arrhythmia

8159 (15.5)

645 (15.1)

449 (9.3)

1095 (10.2)

1611 (13.3)

1851 (18.2)

1331 (21.6)

1177 (27.2)

< 0.01

 Heart failure

2235 (4.3)

154 (3.6)

98 (2.0)

233 (2.2)

373 (3.1)

446 (4.4)

415 (6.7)

516 (11.9)

< 0.01

 PVD

2752 (5.2)

209 (4.9)

178 (3.7)

450 (4.2)

557 (4.6)

583 (5.7)

427 (6.9)

348 (8.0)

< 0.01

 Diabetes

8921 (17.0)

568 (13.3)

511 (10.6)

1313 (12.3)

1845 (15.2)

1933 (19.0)

1442 (23.3)

1309 (30.2)

< 0.01

 Dementia

2549 (4.8)

271 (6.4)

518 (10.7)

653 (6.1)

518 (4.3)

324 (3.2)

170 (2.8)

95 (2.2)

< 0.01

 COPD

4424 (8.4)

297 (7.0)

412 (8.5)

881 (8.2)

1058 (8.7)

892 (8.8)

517 (8.4)

367 (8.5)

0.02

 Asthma

6888 (13.1)

494 (11.6)

679 (14.0)

1418 (13.3)

1642 (13.6)

1292 (12.7)

789 (12.8)

574 (13.3)

< 0.01

 Liver disease

338 (0.6)

45 (1.1)

45 (0.9)

59 (0.6)

79 (0.7)

61 (0.6)

29 (0.5)

20 (0.5)

< 0.01

 Peptic ulcer disease

2974 (5.7)

240 (5.6)

282 (5.8)

594 (5.6)

689 (5.7)

587 (5.8)

346 (5.6)

236 (5.5)

0.98

 RA

1094 (2.1)

96 (2.3)

113 (2.3)

199 (1.9)

259 (2.1)

206 (2.0)

132 (2.1)

89 (2.1)

0.51

 CKD

9366 (17.8)

666 (15.6)

597 (12.4)

1346 (12.7)

1922 (16.0)

2045 (20.1)

1495 (24.2)

1259 (29.2)

< 0.01

  1. BMI body mass index, BP blood pressure, TC total cholesterol, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, PCI percutaneous transluminal coronary intervention, PVD peripheral vascular disease, RA rheumatoid arthritis